Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)

NCT ID: NCT03407755

Last Updated: 2019-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-15

Study Completion Date

2020-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This blinded, randomized study compares the use of air and sulfur hexaflouride (SF6) tamponade in Descemet Membrane Endothelial Keratoplasty.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fuchs' Endothelial Dystrophy Bullous Keratopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients randomized to either air or sulfur hexafluoride (SF6)
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Surgeon and patient masked to choice of intraocular gas. Study coordinator not masked.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Air

Intraocular 100% atmospheric air (anterior chamber).

Group Type ACTIVE_COMPARATOR

Intraocular gas

Intervention Type PROCEDURE

Participants randomized to either air or SF6 gas in the anterior chamber.

SF6

Intraocular 20% sulphur hexaflouride (anterior chamber).

Group Type EXPERIMENTAL

Intraocular gas

Intervention Type PROCEDURE

Participants randomized to either air or SF6 gas in the anterior chamber.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intraocular gas

Participants randomized to either air or SF6 gas in the anterior chamber.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Eligible for DMEK surgey

Exclusion Criteria

Related to ocular health

* Re-DMEK or prior penetrating keratoplasty
* Ocular hypertension resistant to topical medication
* Previous vitrectomy
* Minimally invasive glaucoma devices
* Aphakia
* Anterior chamber or iris claw lens
* Implantable Collamer Lens (ICL)
* Clinically significant corneal scarring
* Central corneal thickness \>750 µm
* BCVA \< 0.1

Related to general health

* Not able to give informed consent
* Inability to position correctly due to organic or psychological condition.

Related to surgical procedure

* Graft diameter \>9 mm or \< 7mm
* Graft central endothelial cell count \< 2000 cells/mm2
* Graft unfolding duration \>1 hour
* Graft morphology grade 4-5
* Significant graft decentration (graft contour not visible in microscope)
* Significant presence of Descemet remnants in the graft-host interface
* Presence of inward folds
* Graft 'stroma-surface' placed facing away from recipient stroma
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Glostrup University Hospital, Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mark Alberti

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Alberti, MD

Role: STUDY_DIRECTOR

Rigshospitalet - Glostrup

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Glostrup Hospital, University of Copenhagen

Glostrup Municipality, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mark Alberti, MD

Role: CONTACT

+4538634823

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mark Alberti

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-17006354

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fuchs' Torsional Phaco Study
NCT00781027 COMPLETED PHASE4